THE WOODLANDS, TX - Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company specializing in nervous system diseases, has announced the upcoming launch of a groundbreaking clinical trial in Uzbekistan. The study will investigate the use of transvascular radiofrequency (RF) ablation as a treatment for pain associated with pancreatic cancer. The firm has received authorization from the Uzbekistan Ethics Committee to open a clinical trial site, with enrollment expected to begin in the first quarter of 2024.
This innovative approach involves a catheter-based technology that senses neural signals and targets nerves for treatment. The proof-of-concept study aims to ablate somatic nerves to alleviate pain in pancreatic cancer patients, a method that has not yet been explored. The trial will enroll 20 subjects at a single site in Uzbekistan, with an additional 5 patients undergoing the procedure for physician training purposes, although their data will not be included in the study's primary analysis. Completion of enrollment is anticipated before the end of the year.
Lori Bisson, CEO of Autonomix, expressed optimism about the technology's potential to improve the quality of life for patients suffering from severe, chronic pain due to pancreatic cancer, which is often inadequately managed by current pharmacological treatments. She emphasized the importance of the study in validating the company's clinical and regulatory strategies for their technology.
Autonomix's catheter-based sensing technology is reported to be significantly more sensitive than existing technologies, potentially enabling precise diagnosis and treatment of peripheral nervous system diseases. The company believes that their technology could offer a superior alternative to systemic drugs like opioids, which can lose effectiveness and cause undesirable side effects, or to imprecise treatments that may miss the target nerves.
The information in this article is based on a press release statement from Autonomix Medical, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.